how do glp-1 agonists work Part 2 of a 3-Part

The incretin hormone glucagon-like peptide 1 (GLP-1) has been implicated in the gutrenal axis and incretin-based therapies might reduce the burden of diabetic kidney disease

Discover how once-monthly maridebart cafraglutide for the treatment of obesity works, its clinical trial evidence, potential eligibility criteria, side effects, and the pathway to NHS access if approved by UK regulators.

Example code lists used to identify covariates are included in supplementary table S2

At the same time, ultra-long-acting injectables are emerging as another theme of innovation

Incretin based therapies with glucagon-like peptide-1 receptor agonists (GLP-1RA) are already established in the treatment of type 2 diabetes

GLP-1s arent for everyone